Characterizing Vericiguat Treatment in Heart Failure: A Multicenter Real-World Study in China.

IF 1.9 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Reviews in cardiovascular medicine Pub Date : 2024-11-29 eCollection Date: 2024-12-01 DOI:10.31083/j.rcm2512427

Qi Wang, Guangchuan Wang, Jiecheng Peng, Jingjing Li, Changlin Ju, Lingxin Pan, Zhiwei Xu, Jun Qian, Zhiquan Liu, Guohong Wu, Xueping Wei, Ji Yan, Xuejun Xiang, Kangyu Chen

{"title":"Characterizing Vericiguat Treatment in Heart Failure: A Multicenter Real-World Study in China.","authors":"Qi Wang, Guangchuan Wang, Jiecheng Peng, Jingjing Li, Changlin Ju, Lingxin Pan, Zhiwei Xu, Jun Qian, Zhiquan Liu, Guohong Wu, Xueping Wei, Ji Yan, Xuejun Xiang, Kangyu Chen","doi":"10.31083/j.rcm2512427","DOIUrl":null,"url":null,"abstract":"Background: Real-world data on the clinical benefit of vericiguat are currently limited. This multicenter, real-world study was conducted to evaluate the clinical characteristics and therapeutic effects of vericiguat in real-world settings.Methods: This study analyzed heart failure (HF) patients who initiated vericiguat treatment from September 2022 to August 2023 across nine hospitals in the Anhui Province, China. The clinical data were retrospectively collected and cases were prospectively followed to assess changes from baseline in N-terminal pro-B type natriuretic peptide (NT-proBNP) at 12 months. Baseline characteristics were compared with those in the VICTORIA trial.Results: Of the 285 patients enrolled, the mean age was 64.8 ± 12.9 years. Of these, 22.8% were female, and 94.7% were classified as New York Heart Association class III-IV. Additionally, 66.4% had a reduced ejection fraction with a median NT-proBNP level of 2915 pg/mL. Vericiguat therapy was initiated during hospitalization in 223 patients (78.2%), with 105 (37.1%) receiving quadruple anti-HF therapy. Only 44.9% met the VICTORIA trial inclusion criteria.Conclusions: In this multicenter, real-world study of vericiguat in Anhui Province, only 44.9% of vericiguat users met the inclusion criteria for the VICTORIA trial. This suggests that vericiguat is being applied more broadly by physicians to treat HF in real clinical settings.","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"25 12","pages":"427"},"PeriodicalIF":1.9000,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11683721/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in cardiovascular medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31083/j.rcm2512427","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Real-world data on the clinical benefit of vericiguat are currently limited. This multicenter, real-world study was conducted to evaluate the clinical characteristics and therapeutic effects of vericiguat in real-world settings.

Methods: This study analyzed heart failure (HF) patients who initiated vericiguat treatment from September 2022 to August 2023 across nine hospitals in the Anhui Province, China. The clinical data were retrospectively collected and cases were prospectively followed to assess changes from baseline in N-terminal pro-B type natriuretic peptide (NT-proBNP) at 12 months. Baseline characteristics were compared with those in the VICTORIA trial.

Results: Of the 285 patients enrolled, the mean age was 64.8 ± 12.9 years. Of these, 22.8% were female, and 94.7% were classified as New York Heart Association class III-IV. Additionally, 66.4% had a reduced ejection fraction with a median NT-proBNP level of 2915 pg/mL. Vericiguat therapy was initiated during hospitalization in 223 patients (78.2%), with 105 (37.1%) receiving quadruple anti-HF therapy. Only 44.9% met the VICTORIA trial inclusion criteria.

Conclusions: In this multicenter, real-world study of vericiguat in Anhui Province, only 44.9% of vericiguat users met the inclusion criteria for the VICTORIA trial. This suggests that vericiguat is being applied more broadly by physicians to treat HF in real clinical settings.

查看原文本刊更多论文

心力衰竭患者的韦立克治疗特点：中国多中心真实世界研究

背景：目前关于vericiguat临床获益的真实数据有限。这项多中心、真实世界的研究旨在评估vericiguat在真实世界中的临床特征和治疗效果。方法：本研究分析了中国安徽省9家医院在2022年9月至2023年8月期间接受vericiguat治疗的心力衰竭（HF）患者。回顾性收集临床资料，并对病例进行前瞻性随访，以评估12个月时n端前b型利钠肽（NT-proBNP）的基线变化。基线特征与VICTORIA试验比较。结果：285例入组患者的平均年龄为64.8±12.9岁。其中22.8%为女性，94.7%为纽约心脏协会III-IV类。此外，66.4%的患者射血分数降低，NT-proBNP中位水平为2915 pg/mL。223例（78.2%）患者在住院期间开始使用Vericiguat治疗，105例（37.1%）患者接受了四联抗hf治疗。只有44.9%符合VICTORIA试验纳入标准。结论：在安徽省的多中心、真实世界的vericiguat研究中，只有44.9%的vericiguat使用者符合VICTORIA试验的纳入标准。这表明vericiguat在实际临床环境中被医生广泛应用于治疗心衰。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Reviews in cardiovascular medicine 医学-心血管系统

CiteScore

2.70

自引率

3.70%

发文量

377

审稿时长

1 months

期刊介绍： RCM is an international, peer-reviewed, open access journal. RCM publishes research articles, review papers and short communications on cardiovascular medicine as well as research on cardiovascular disease. We aim to provide a forum for publishing papers which explore the pathogenesis and promote the progression of cardiac and vascular diseases. We also seek to establish an interdisciplinary platform, focusing on translational issues, to facilitate the advancement of research, clinical treatment and diagnostic procedures. Heart surgery, cardiovascular imaging, risk factors and various clinical cardiac & vascular research will be considered.